Durability of virologic response, risk of de novo hepatocellular carcinoma, liver function and stiffness 2  years after treatment with ombitasvir/paritaprevir/ritonavir±dasabuvir±ribavirin in the AMBER, real‐world experience study

Journal of Viral Hepatitis, EarlyView.

Source: Journal of Viral Hepatitis - July 3, 2018 Category: Infectious Diseases Authors: R. Flisiak , E. Janczewska , M. Łucejko , E. Karpińska , D. Zarębska‐Michaluk , K. Nazzal , B. Bolewska , J. Białkowska , H. Berak , K. Fleischer‐Stępniewska , K. Tomasiewicz , K. Karwowska , K. Source Type: research